Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.44 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723381 | 1.00 | HPGD (0.56) | HPGDMAPK1POLBALDH1A1HTT | |
| SCHEMBL21752112 | 0.85 | HPGD (0.48) | HPGDPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL21752111 | 0.81 | PARP1 (0.44) | HPGDPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL27351823 | 0.80 | HPGD (0.51) | HPGDPOLBALDH1A1HTTCYP2C19 | |
| SCHEMBL4566340 | 0.80 | KMO (0.50) | HPGDPOLBALDH1A1HTTCYP2C19 | |
| SCHEMBL14650448 | 0.76 | HPGD (0.45) | HPGDMAPK1POLBALDH1A1HTT | |
| SCHEMBL169922 | 0.76 | MCL1 (0.49) | HPGDPOLBALDH1A1HTTCYP2C19 | |
| SCHEMBL1639877 | 0.75 | HSD11B1 (0.57) | HPGDALDH1A1MEN1KMT2APARP1 | |
| SCHEMBL18707034 | 0.74 | MEN1 (0.59) | HPGDPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL29980474 | 0.72 | GAA (0.48) | HPGDPOLBALDH1A1TP53L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| US-12435066-B2 | Substituted tricyclic compounds | LUPIN LIMITED (IN) | 2025-10-07 | — | — | US | disclosed |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | MEDSHINE DISCOVERY INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-4065575-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2024-01-31 | — | — | EP | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| EP-4219493-A1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230119316-A1 | Substituted Tricyclic Compounds | LUPIN LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| EP-3728254-B1 | BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2023-01-19 | — | — | US | disclosed |
| EP-4081521-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| EP-4065575-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022199670-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| WO-2021130731-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130731-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021105960-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-06-03 | — | — | WO | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| WO-2020254451-A1 | ANTICANCER COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-24 | — | — | WO | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013778-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | SOS1, RSU1, KSR1 | HPGD 3931/4885MAPK1 47/4885POLB 1684/4885 |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | HPGD 3837/4885MAPK1 30/4885POLB 4334/4885 |
| US-20240208945-A1 | 6-CARBAMATE SUBSTITUTED HETEROARYL RING DERIVATIVES | CYP3A7, UGT2B7, CYP51A1 | HPGD 2710/4885MAPK1 4121/4885POLB 3068/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | HPGD 3877/4885MAPK1 44/4885POLB 4404/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | HPGD 3813/4885MAPK1 38/4885POLB 4281/4885 |
| US-20230119316-A1 | Substituted Tricyclic Compounds | SOS1, RSU1, KSR1 | HPGD 4008/4885MAPK1 52/4885POLB 1789/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | HPGD 3835/4885MAPK1 47/4885POLB 4358/4885 |
| US-12435066-B2 | Substituted tricyclic compounds | SOS1, RSU1, KSR1 | HPGD 3931/4885MAPK1 47/4885POLB 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.